Vaspin
- Known as:
- Vaspin
- Catalog number:
- RD172097100
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Biovend
- Gene target:
- Vaspin
Related genes to: Vaspin
- Gene:
- SERPINA12 NIH gene
- Name:
- serpin family A member 12
- Previous symbol:
- -
- Synonyms:
- OL-64, Vaspin
- Chromosome:
- 14q32.13
- Locus Type:
- gene with protein product
- Date approved:
- 2004-05-21
- Date modifiied:
- 2016-04-06
Related products to: Vaspin
Anti-Human VaspinAnti-Human VaspinAnti-Human VaspinAnti-human Vaspin, bt, Source: Polyclonal bt. Rabbit, PABAnti-human Vaspin, bt, Source: Polyclonal bt. Rabbit, PABAnti-human Vaspin, bt, Source: Polyclonal bt. Rabbit, PABAnti-human Vaspin, Source: Polyclonal Rabbit, PABAnti-human Vaspin, Source: Polyclonal Rabbit, PABAnti-human Vaspin, Source: Polyclonal Rabbit, PABAntibody to Visceral Adipose Tissue Derived Serine Protease Inhibitor (Vaspin) Organism: Homo sapiens (Human) Type: Polyclonal Source: RabbitAntibody to Visceral Adipose Tissue Derived Serine Protease Inhibitor (Vaspin) Organism: Homo sapiens (Human) Type: Polyclonal Source: RabbitAntibody to Visceral Adipose Tissue Derived Serine Protease Inhibitor (Vaspin) Organism: Mus musculus (Mouse) Type: Polyclonal Source: RabbitAntibody to Visceral Adipose Tissue Derived Serine Protease Inhibitor (Vaspin) Organism: Mus musculus (Mouse) Type: Polyclonal Source: RabbitAntibody to Visceral Adipose Tissue Derived Serine Protease Inhibitor (Vaspin) Organism: Rattus norvegicus (Rat) Type: Polyclonal Source: RabbitAntibody to Visceral Adipose Tissue Derived Serine Protease Inhibitor (Vaspin) Organism: Rattus norvegicus (Rat) Type: Polyclonal Source: Rabbit Related articles to: Vaspin
- Palmoplantar keratoderma (PPK) is a heterogeneous group of skin diseases, characterised by excessive keratinization and hyperplasia of the palms and soles. However, accurate molecular diagnosis remains challenging due to the low prevalence of hereditary forms. This study analysed the phenotype and genotype distribution in a large cohort of Chinese patients with PPK, aiming to clarify the genetic aetiology and genotype-phenotype correlations. We further validated the pathogenicity of biallelic SERPINA12 variants identified in four patients. A total of 424 patients with PPK were enrolled from 2010 to 2023. Of these, 97.6% (414/424) presented with diffuse PPK, predominantly Nagashima-type PPK (NPPK), with rare cases of Olmsted, Meleda and Bothnia types. Focal PPK accounted for 1.4%, with less than 1% for striate and punctate types, respectively. Genetic testing was performed in 380 patients. Overall, 328 patients harboured pathogenic or likely pathogenic (P/LP) variants to achieve definite molecular diagnosis; none carried only variants of uncertain significance (VUS) and the remaining 52 patients had no candidate disease-associated variants identified. All patients underwent testing with an in-house customised SERPINB7 gene hotspot panel test for c.796C>T, c.522_523insT, c.806_818delinsT and c.650_653delCTGT variants. In 80% (304/380) patients, hotspot variants in SERPINB7 were identified, with c.796C>T (77%) and c.522_523insT (16%) being the most frequent. Patients not diagnosed with a hotspot variant further underwent whole-exome sequencing (WES), which identified confirmed pathogenic (P) or likely pathogenic (LP) variants in TRPV3 (c.1246C>T, c.1703G>A, c.1247G>A), AQP5 (c.530 T>A, c.367A>T), SLURP1 (c.154A>G), KRT9 (c.1373 T>C), KRT6A (c.947G>C) and KRT16 (c.379C>T). In addition, three recurrent SERPINA12 variants were identified, enriching the gene spectrum of diffuse PPK. This study established the largest cohort of patients with SERPINB7 variants reported to date, identifying that NPPK is the predominant subtype among Chinese populations. Variants in SERPINA12 are likely correlated with diffuse palmoplantar keratoderma, consistent with the clinical manifestations of NPPK. Additionally, a diagnostic panel targeting ancestral SERPINB7 founder variants would markedly improve the molecular diagnostic yield in Chinese patients. - Source: PubMed
Wang XinyiSun WeiweiZhang ChengWang YumengLi MingyangGe HongsongZheng LuyaoCao QiaoyuLi YueWang ShucuiZhao AnqiPan ChaonanZeng YibinLi Ming - Interest in identifying biomarkers that reflect spine condition and support therapy monitoring has grown. Since low-grade inflammation and comorbidities can complicate treatment, they should be considered in research. Vaspin (SERPINA12) has been linked to low back pain (LBP) severity and disability, highlighting its potential as a biomarker connecting LBP and adipose tissue inflammation. The study aimed to assess the effect of traction therapy on serum vaspin levels and compare responses between women with obesity and normal BMI. A secondary aim was to explore associations between vaspin, LBP severity, disability scores, and selected inflammatory markers. It is a prospective clinical trial. Women aged 34-50 years with chronic LBP were divided into two groups: those with normal BMI and those with obesity. Both groups underwent 20 30-min sessions of lumbar traction therapy. At baseline and after therapy, LBP intensity, the Oswestry Disability Index (ODI), and the Roland-Morris Disability Questionnaire (RMDQ) were assessed, and blood samples were collected for analysis of vaspin, RANTES, interleukin (IL)-2, IL-17A, IL-4, and IL-10. After completing the traction therapy, there was a significant decrease in LBP, ODI, and RMDQ and an increase in the circulating levels of IL-10, regardless of BMI. However, vaspin concentration increased significantly only in women with normal BMI. Post-therapy, vaspin negatively correlated with ODI. IL-4 and IL-17A levels also correlated with vaspin, positively in women with normal BMI and negatively in those with obesity. Obesity-related inflammation may alter the biochemical response to traction therapy. Increases in vaspin concentration were found exclusively in women with normal BMI, indicating a possible BMI-dependent association between circulating vaspin concentrations and response to therapy.Registration: The study was registered at ClinicalTrials.gov with the ID number NCT04507074. - Source: PubMed
Publication date: 2026/06/29
Ratajczak MarzenaKalinkovich AlexanderLivshits Gregory - - Source: PubMed
Publication date: 2026/06/14
Pan LuluBu Zhangyu - SERPINA12 is a member of the serpin superfamily that has been extensively studied in metabolic and inflammatory disorders. In recent years, increasing evidence has highlighted its emerging role in skin physiology and dermatological diseases. SERPINA12 is expressed in multiple skin cell types, including keratinocytes and dermal fibroblasts, where it participates in the regulation of inflammation, cellular proliferation, differentiation, and tissue homeostasis. Dysregulation of SERPINA12 has been implicated in several skin disorders. In psoriasis, altered SERPINA12 expression is associated with chronic inflammation, immune dysregulation, and abnormal keratinocyte proliferation, suggesting a potential modulatory role in psoriatic pathogenesis. Furthermore, emerging studies suggest a possible involvement of SERPINA12 in palmoplantar keratoderma, where it may contribute to aberrant keratinization and epidermal barrier dysfunction. This review summarizes current knowledge on the expression patterns, biological functions, and molecular mechanisms of SERPINA12 in the skin, with a particular focus on adipocytes, psoriasis, and palmoplantar keratoderma. Understanding the role of SERPINA12 in cutaneous biology may provide new insights into disease pathogenesis and identify potential therapeutic targets for skin disorders. - Source: PubMed
Publication date: 2026/04/27
Xiao ZhenzhenWang FeiLi RuiTan Yingjian - Cardiometabolic diseases are chronic conditions arising from the common pathophysiology of metabolic and cardiovascular disorders accompanied by risk factors such as insulin resistance, obesity, type 2 diabetes, metabolic syndrome, and hypertension. In recent years, the relationship between adipokines such as PAI-1 and vaspin and these diseases has attracted increasing interest. PAI-1 increases cardiovascular risks by inhibiting fibrinolysis, and high PAI-1 levels are associated with obesity and insulin resistance. Vaspin, on the other hand, may have an inhibitory effect on the development of type 2 diabetes and metabolic syndrome by increasing insulin sensitivity. Considering the effects of dietary and lifestyle factors on these molecules, PAI-1 and vaspin are thought to have potential as early biomarkers and therapeutic targets. However, conflicting findings in the literature necessitate further research. Alongside lifestyle interventions based on healthy eating and exercise, changes in PAI-1 and vaspin levels show promise as potential biomarkers for the early diagnosis and prevention of cardiometabolic disorders and the development of personalized treatment strategies. Further research is required to better clarify the molecular mechanisms regulating PAI-1 and vaspin and to determine their potential clinical applications in the prevention and management of cardiometabolic diseases. - Source: PubMed
Publication date: 2026/03/26
Kocabas SuleSanlier Nevin